Deerfield, Ill.-based devicemaker Baxter International said Dec. 2 it will acquire Sanofi’s Seprafilm Adhesion Barrier device and related assets for $350 million. Adhesion prevention products such as ...

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, has completed its previously announced acquisition of Seprafilm Adhesion Barrier and ...

To describe the long-term surgical outcomes of four patients treated for retinal detachment using Seprafilm as a novel technique. Retinal breaks in four eyes were covered with Seprafilm using a ...

Sanofi has moved to offload its Seprafilm surgical barrier business, setting up a large infusion of cash for early next year as its new CEO prepares to unveil his new strategic priorities for the ...

(Reuters) - Genzyme Corp agreed to pay $32.59 million, admit wrongdoing and enter a deferred prosecution agreement to resolve U.S. criminal charges over its marketing of the surgical implant Seprafilm ...

Public Citizen wants FDA to pull a membrane device from market. Nancy Crotti A public watchdog group has petitioned FDA to pull Sanofi's Seprafilm from the market, citing the agency's own reports of ...

PARIS — France’s Sanofi has agreed to sell its Seprafilm unit, which makes specialist surgical products, to U.S.-based Baxter for $350 million, a source familiar with the matter said on Monday. The ...

Delivers on Baxter’s strategy to acquire products that are a strong fit with the company’s leading hemostat and sealant portfolio Plans to support the product through Baxter’s dedicated surgery ...

(RTTNews) - Medical products company Baxter International Inc. (BAX) agreed Monday to acquire Seprafilm Adhesion Barrier and related assets from French drug maker Sanofi (SNYNF, SNY) to expand its ...

Acquired product line is strong complement to the company’s leading Advanced Surgery portfolio Global integration process begins immediately to manage successful transition with customers and ...

Sept 3 (Reuters) - Genzyme Corp agreed to pay $32.59 million, admit wrongdoing and enter a deferred prosecution agreement to resolve U.S. criminal charges over its marketing of the surgical implant ...